1 January 2002 in Journal of Psychosomatic Obstetrics & Gynecology
This study evaluates the distress experienced by women attending gynecology outpatient clinics (GOCs). We investigate causes of this distress and explore women's own experience of their distress. A questionnaire survey of 797 women attending GOCs was carried out, both quantitative and qualitative analyses were undertaken. Thirty-five percent of women showed clinical levels of anxiety, 13% had clinically significant depression and half reported feeling distressed. A range of feelings was reported, though commonly mixed emotions were expressed. Women had a low sense of personal control and uncertainty in relation to their gynecologic problem. Both coincidental stress, such as life changes, and the direct consequences of the gynecologic problem were predictive of anxiety. Qualitative analysis suggested four ways in which women experienced their distress and the gynecologic problem: (i) gynecologic symptoms were a direct cause of distress, (ii) gynecologic symptoms caused distress indirectly through reactions to diagnosis and treatment, (iii) gynecologic symptoms caused distress because of their impact on relationships, social life and self identity and (iv) distress was unrelated to the gynecologic symptoms. Results highlight diversity and complexity in women's experiences and support the need for a fuller understanding of distress in this group in order to meet their needs adequately and appropriately.
1 January 2023 in Arhiv za farmaciju
Hydrogen sulfide (H 2 S) is the youngest member of the gasotransmitters family consisting of nitric oxide (NO) and carbon monoxide (CO). This signalling molecule is implicated in the regulation of a wide range of processes, such as inflammation, pain, and tissue repair, and has an important role in signalling processes affecting cardiovascular health, either as an independent effector or as an enhancer of the NO system. With the discovery of the H 2 S role in the pathogenesis of many diseases, the development of new pharmaceuticals that could be useful in conditions with disturbed levels of endogenous H 2 S began. Today, the development of H 2 S-releasing drugs has reached the level of clinical studies. Drugs such as SG1002, aimed at the treatment of heart failure, and ATB-346, aimed at the treatment of arthritis, have been tested in Phase I/II clinical studies and have shown significant therapeutic potential. Additionally, it has been shown that some already known drugs, such as zofenopril, produce part of their beneficial effects by releasing H 2 S. Evidence from clinical studies presented in this paper encourages further clinical testing of H 2 S-based therapeutics and the possibility of their application in a wide range of diseases, such as hypertension, diabetes and chronic kidney disease.
19 September 2022 in Journal of Cardiac Surgery